WelCOME TO Trixeo.IE for
Healthcare Professionals

This site is intended for healthcare professionals registered in Ireland.

Trixeo Aerosphere® contains formoterol fumarate, glycopyrronium and budesonide. Trixeo Aerosphere® is an inhaled therapy indicated as a maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.1

How to use the inhaler

Learn how to prepare your inhaler, using your inhaler, priming your inhaler, cleaning your inhaler, …

Read more

Inhaler information

If a dose is missed, it should be taken as soon as possible, and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose…

Read more

Safety Data

The most commonly reported adverse reactions in patients receiving this medicinal product were pneumonia (4.6%), headache (2.7%) and urinary tract infection (2.7%)1…
Read more

How to Prescribe Trixeo

Trixeo Aeroshpere is recommended to be prescribed as follows…

Read more

ACT ON COPD

It’s never too early to act on COPD Put prevention of exacerbation and early death at the centre of COPD management. It is time to ACT. ACT on COPD. 

Read more

ETHOS TRIAL

ETHOS was a 52-week trial that compared TRIXEO with GFF pMDI (LAMA/LABA) and BFF pMDI (ICS/LABA).1

Read more

KRONOS TRIAL

KRONOS was a 24-week trial that compared TRIXEO with GFF pMDI (LAMA/LABA) and BFF pMDI or DPI (ICS/LABA).1

Read more